The clinical significance of IDH mutations in essential thrombocythemia and primary myelofibrosis
View/ Open
Access
info:eu-repo/semantics/openAccessAttribution 3.0 United Stateshttp://creativecommons.org/licenses/by/3.0/us/Date
2016Author
Yönal Hindilerden, İpekDağlar Aday, Aynur
Hindilerden, Fehmi
Akadam Teker, Başak
Yılmaz, Ceylan
Nalçacı, Meliha
Yavuz, Akif Selim
Sargın, Deniz
Metadata
Show full item recordCitation
Yönal Hindilerden, İ., Dağlar Aday, A., Hindilerden, F., Akadam Teker, B., Yılmaz, C., Nalçacı, M. ... Sargın, D. (2016). The clinical significance of IDH mutations in essential thrombocythemia and primary myelofibrosis. Journal of Clinical Medicine Research, 8(1), 29-39. https://dx.doi.org/10.14740/jocmr2405wAbstract
Background: Limited data exist regarding impact of IDH mutations in Philadelphia-negative myeloproliferative neoplasms (Ph-negative MPNs). Prognostic significance of IDH mutations was asessed in 184 Ph-negative MPN patients - 107 essential thrombocythemia (ET) and 77 primary myelofibrosis (PMF). Methods: High-resolution melting (HRM) analysis was used to detect IDH1 and IDH2 mutations. Results: PMF and ET patients showed no significant difference for prevalence of IDH mutations. Mutant IDH (IDH1 or IDH2) was documented in five of PMF (6.5%) and two of ET patients (1.9%). IDH mutations in ET patients included one IDH1 R132C and one IDH2 R140Q. Of the five IDH-mutated PMF patients, four (80%) displayed IDH1 (three IDH1 R132C and one IDH1 R132S) and one (20%) carried IDH2 (IDH2 R140Q) mutation. Sixty percent (three in five) of IDH-mutated PMF patients carried JAK2V617F with following allele burdens: 31-50%, 5-12.5% and 31-50%, respectively. Three of 77 PMF patients (3.9%) simultaneously harbored IDH and JAK2V617F mutations. IDH mutations in PMF showed a trend towards higher rate in females (100% and 52.8%, respectively). Bleeding complications were significantly higher in IDH-mutated PMF patients compared to IDH wild-type counterparts. Trend towards a lower prevalance of acetylsalicylic acid (ASA) use was present in IDH mutant PMF patients compared to wild-type counterparts (20% and 63.9%, respectively). Death rate was higher in IDH-mutated PMF patients compared to IDH wild-type PMF patients (60% and 15.3%). In univariate analysis, a significantly shorter leukemia-free survival (LFS) was observed in IDH-mutated PMF patients. Conclusions: We conclude that IDH mutations indicate a risk for leukemic transformation in PMF.
Source
Journal of Clinical Medicine ResearchVolume
8Issue
1Collections
- Makale Koleksiyonu [3642]
- PubMed İndeksli Yayınlar Koleksiyonu [4039]
The following license files are associated with this item: